Autopsy report · NCT04777851

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

“The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve the target sample size within a reasonable timeframe. Consequently, a business decision has been made to discontinue funding for the trial.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 8 months before it started.
• Ran for about 2 years 4 months before it stopped.
• 45 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Translational Research in Oncology

Sponsor type

University, hospital or other

Conditions

Carcinoma, Hepatocellular

Interventions

Regorafenib in combination with pembrolizumab; Loco-regional therapy

Participants

45

Sites

26

Countries

Belgium, France, Georgia, Germany, Hong Kong, Italy, Romania, Serbia, South Korea, Spain, Taiwan, Turkey (Türkiye) and more

Trials that died the same way

• A Study Of PF-06664178 In Patients With Advanced Solid Tumors
  “The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results.” (79% match in meaning)
• Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
  “Company decision to discontinue trial” (78% match in meaning)
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
  “The study was terminated due to the sponsor's decision to discontinue the clinical trial.” (75% match in meaning)
• Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
  “The trial is closing due to findings from a related study, prompting the sponsor to discontinue development and end this study.” (74% match in meaning)
• A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
  “Trial terminated early per business decision” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.